論文・総説 - 原田　浩之

261. Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba S, Nishioka Y, Kawada M, Harada H, Kato Y. Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget. 2018.04; 9 (32): 22480-22497. ( PubMed, DOI )

262. Sato M, Harada H, Nagata C, Suzuki K. A case of Ectomesenchymal Chondromyxoid Tumor on the tongue Journal of Oral and Maxillofacial Surgery, Medicine. 2018.03; 30 (2): 134-137. ( DOI )

263. Nishii N, Tachinami H, Kondo Y, Xia Y, Kashima Y, Ohno T, Nagai S, Li L, Lau W, Harada H, Azuma M. Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy. Oncotarget. 2018.03; 9 (17): 13301-13312. ( PubMed, DOI )

264. Ando Kentaro, Nakamura Yuji, Hagiwara-Nagasawa Mihoko, Harada Hiroyuki, Miyamoto Hiroyoshi, Inamura Naoki, Takagi Kan, Goto Ai, Chiba Koki, Lubna Nur Jaharat, Izumi-Nakaseko Hiroko, Naito Atsuhiko T., Sugiyama Atsushi. テルフェナジンの薬力学的および薬物動態学的プロファイルの変動ならびにその活性誘導体であるフェキソフェナジンのトルサード・ド・ポワント誘導リスクについて検討するための、ハロタン麻酔イヌを対象としたクロスオーバー試験によるテルフェナジンとフェキソフェナジンの電気薬理学的作用の比較(Comparison of electropharmacological effects between terfenadine and its active derivative fexofenadine using a cross-over study in halothane-anesthetized dogs to analyze variability of pharmacodynamic and pharmacokinetic profiles of terfenadine and torsadogenic risk of fexofenadine) The Journal of Toxicological Sciences. 2018.03; 43 (1-3): 183-192. ( 医中誌 )

265. Sato Masaru, Harada Hiroyuki, Nagata Chigusa, Suzuki Keiko. 舌のectomesenchymal chondromyxoid tumorの1例(A case of ectomesenchymal chondromyxoid tumor of the tongue) Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 2018.03; 30 (2): 134-137. ( 医中誌 )

266. Ohata Y, Tsuchiya M, Hirai H, Yamaguchi S, Akashi T, Sakamoto K, Yamaguchi A, Ikeda T, Kayamori K. Leukemia inhibitory factor produced by fibroblasts within tumor stroma participates in invasion of oral squamous cell carcinoma PLoS One. 2018.02; e0191865.

267. Jiaranuchart S, Kaida A, Onozato Y, Harada H, Miura M. DNA damage response following X-irradiation in oral cancer lines HSC3 and HSC4 Archives of Oral Biology. 2018.02; 90 1-8. ( PubMed, DOI )

268. Kuroshima T, Wada M, Sato T, Takano M, and Makino S. G-CSF producing oral carcinoma with diffuse uptake of FDG in the bone marrow: A case report Oncology Letters. 2018.01; 15 (1): 1241-1245.

269. Nishii N, Tachinami H, Kondo Y, Xia Y, Kashima Y, Ohno T, Nagai S, Li L, Lau W, Harada H, Azuma M. Systemic administration of a TLR7 agonist attenuates regulatory T cells by dend+E11:AB11ritic cell modification and overcomes resistance to PD-L1 blockade therapy Oncotarget. 2018.01; 9 13301-13312. ( DOI )

270. Takemoto T, Kabasawa Y, Higuchi Y, Tabata Y, Aoki K, Tamura Y, Harada H. Combination of the RANKL-binding peptide W9 and bFGF induces ectopic bone regeneration in the rat calvarial defect mode Dental, Oral and Craniofacial Research. 2017.12; 4 (3): 2-7. ( DOI )

271. Harada H, Suehiro S, Murakami D, Nakahara R, Ujihara T, Shimizu T, Miyama Y, Katsuyama Y, Hayasaka K, Tounou S. Clinical impact of prophylactic clip closure of mucosal defects after colorectal endoscopic submucosal dissection. Endoscopy international open. 2017.12; 5 (12): E1165-E1171. ( PubMed, DOI )

272. Harada Hiroyuki, Shinohara Shogo, Takebayashi Shinji, Kikuchi Masahiro, Fujiwara Keizo, Michida Tetsuhiko, Yamamoto Ryosuke, Hayashi Kazuki, Saida Koji, Naito Yasushi. アルコール摂取後の顔面潮紅は上部消化管癌の同時性または異時性リスクが高いことの予測因子である(Facial flushing after alcohol intake as a predictor for a high risk of synchronous or metachronous cancer of the upper gastrointestinal tract) Japanese Journal of Clinical Oncology. 2017.12; 47 (12): 1123-1128. ( 医中誌 )

273. Itai S, Yamada S, Kaneko MK, Harada H, Kagawa Y, Konnai S, Kato Y. Expression of Cat Podoplanin in Feline Squamous Cell Carcinomas. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2017.12; 36 (6): 243-250. ( PubMed, DOI )

274. マハムド・エルバシュティ , アメル・アスウェヘリー , 服部 麻里子, 隅田 由香, 道 泰之, 鵜澤 成一, 山口 聡, 原田 浩之, 谷口 尚. 上顎切除患者に対する顎顔面補綴治療上の考慮事項に関する外科医の意識調査(Surgeons' Awareness of the Considerations for Prosthetic Rehabilitation in Maxillectomy Patients) 顎顔面補綴. 2017.12; 40 (2): 28-36. ( 医中誌 )

275. Itai S, Yamada S, Kaneko MK, Chang YW, Harada H, Kato Y. Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2017.12; 36 (6): 272-281. ( PubMed, DOI )

276. Yamada S, Itai S, Nakamura T, Chang YW, Harada H, Suzuki H, Kaneko MK, Kato Y. Establishment of H(2)Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2017.12; 36 (6): 287-290. ( PubMed, DOI )

277. Itai S, Yamada S, Kaneko MK, Harada H, Kagawa Y, Konnai S, Kato Y. Expression of cat podoplanin in feline squamous cell carcinomas Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2017.11; ( DOI )

278. Yamada S, Itai S, Nakamura T, Chang YW, Harada H, Suzuki H, Kaneko MK, Kato Y. Establishment of H2Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2017.11; ( DOI )

279. Itai S, Yamada S, Kaneko MK, Chang YW, Harada, H, Kato Y. Establishment of EMab-134, a sensitive and specific anti-epidermal growth factor receptor monoclonal antibody for detecting squamous cell carcinoma cells of the oral cavity Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2017.11; ( DOI )

280. Ohata Y, Tatsuzawa A, Ohyama Y, Ichikawa A, Mochizuki Y, Ishibashi S, Itakura Y, Sakamoto K, Ikeda T, Kitagawa M, Yamamoto K. A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer Human Pathology. 2017.11; 69 129-139. ( DOI )